388 Market St #1300, San Francisco, CA 94111, USA

©2018 by Cellastra Inc. Proudly created with Wix.com

 CELLASTRA INC

DISRUPTIVE GENE THERAPY
TARGETING ROOT CAUSES OF SCARRING

 

FOR GLOBAL UNMET NEEDS IN SURGERY, TRAUMA AND  BURN  INJURIES

CELLASTRA NEWS

CELLASTRA'S GENE THERAPY REPORT 1 November 2019: Recent Approvals. IPOs and Aquisitions -

TOP GENE THERAPY COMPANIES

LINK 

CELLASTRA EXECUTIVE SUMMARY

INVESTOR PRESENTATION

PRESS RELEASES

CELLASTRA INC 07/15/2019

 

Cellastra announces filing of global patent application for prevention of scars and adhesions.

                                         READ MORE

CELLASTRA INC 06/24/2019

Cellastra announces collaboration with leading academic laboratory in Canada for manufacturing and testing of a novel gene vector programmed for scar prevention.

Preparing for clinical study in burn injuries

                                       READ MORE

CELLASTRA INC 04/04/2019

 

Cellastra announces updates from American Burn Association's Annual Meeting in Las Vegas, April 2-5, 2019

Prof. Folke Sjoberg , Cellastra Scientific Advisory Board Memberawarded to give the Everett Idris Evans Memorial Lecture on frontiers in burn injury treatment

Cellastra prepares for  clinical study in burn injury

                                           READ MORE

ASSOCIATED PRESS 1/15/2019

 

FDA planning new guidance, hires in cell and gene therapies for 2019

The FDA plans to hire at least 50 new clinical reviewers tasked with assessing cell and gene therapies to prepare for what the agency describes as a surge of cutting-edge products currently entering early development.

The FDA predicts  10 to 20 cell and gene therapy approvals each year by2025. READ MORE

01/07/2019

Cellastra announces 10M USD Series A capital call to support new gene therapy program for scar prevention after surgery and burn injuries

Appoints gene therapy leadership in new management positions        READ MORE

12/01/2018018

Cellastra announces the appointment accounting veteran Bruce Phillips as new Chief Financial Officer.  READ MORE

11/01/2018

Cellastra announces acquisition of a novel gene therapy platform including global development and commercialization rights for scar prevention

 

  • First indication will be prevention of scarring and adhesions after surgery as well as burn injuries. Other indications to follow will include scar prevention after hip and knee replacement

  • One treatment may provide scar prevention for many months.

READ MORE